Ives Jeffrey L. 4
4 · Acumen Pharmaceuticals, Inc. · Filed Aug 18, 2023
Insider Transaction Report
Form 4
Ives Jeffrey L.
Director
Transactions
- Sale
Common Stock
2023-08-17$6.66/sh−2,800$18,648→ 0 total - Exercise/Conversion
Common Stock
2023-08-17$0.72/sh+39,149$28,187→ 39,149 total - Exercise/Conversion
Common Stock
2023-08-17$1.19/sh+2,800$3,332→ 2,800 total - Exercise/Conversion
Stock Option (right to buy)
2023-08-17−39,149→ 0 totalExercise: $0.72Exp: 2029-03-01→ Common Stock (39,149 underlying) - Sale
Common Stock
2023-08-17$6.48/sh−39,149$253,686→ 0 total - Exercise/Conversion
Stock Option (right to buy)
2023-08-17−2,800→ 0 totalExercise: $1.19Exp: 2031-01-03→ Common Stock (2,800 underlying)
Footnotes (2)
- [F1]The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on May 17, 2023.
- [F2]The option is fully vested.